Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MTPC: Pharma Sales Up 2%; Remicade, Talion Drive Business
May 25, 2009
- Takeda: Record-High Sales of ¥1,538 Bil.
May 25, 2009
- DSP: New Products Make Up for Decreases in Sales of Amlodin
May 25, 2009
- Novartis to Make Everolimus Blockbuster in 5 Years: Mr D. Epstein
May 25, 2009
- REGULATORY NEWS IN BRIEF
May 25, 2009
- BUSINESS NEWS IN BRIEF
May 25, 2009
- FDA Approves ACTOplus met XR: Takeda
May 25, 2009
- 31 Generics of Cravit from 23 Firms Included in NHI Price List
May 25, 2009
- First Generics Listed for 13 APIs
May 25, 2009
- Kyowa Kirin: Nesp Injection Plastic Syringe
May 25, 2009
- Mediceo Paltac to Invite 1,000 Employees to Early Retirement
May 25, 2009
- IMS Health Revises Its Forecast for Global Drug Sales Downward
May 25, 2009
- Kyowa Kirin Licenses Anti-LIGHT Antibody to sanofi-aventis
May 25, 2009
- R&D NEWS IN BRIEF
May 18, 2009
- Japan Provides High-Quality Data in Multinational Trials: Prof. Sato
May 18, 2009
- JPMA to Support Development of 14 Unapproved Drugs
May 18, 2009
- Nichi-Iko Opens New Office in Tokyo
May 18, 2009
- MTPC Holds Event to Promote Use of Generics
May 18, 2009
- Original Drugs Should Give Way to Generics when They Go Off-Patent: Mr Kinoshita
May 18, 2009
- BI Records Growth Rates Higher than Industry Average for 9th Year Running
May 18, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…